Niagen Bioscience, Inc. — Director's Dealing 2012

Feb 24, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-02-21

Reporting Person: Heim Debra (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	750000	Direct
Common Stock	75000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$0.79	2017-02-21	Common Stock (750000)		Direct
Employee Stock Option (Right to Buy)	$0.79	2017-02-21	Common Stock (750000)		Direct

Footnotes

F1: Shares of restricted stock were purchased at a price of $0.001 per share pursuant to the Executive Employment Agreement dated February 21, 2012, and shall vest in full on February 1, 2015, provided that a certain Stock Performance Condition is met.

F2: Shares of restricted stock were granted pursuant to the Executive Employment Agreement dated February 21, 2012, and were immediately vested.

F3: Such Options are subject to the following vesting schedule: one third shall vest and become exercisable on the first anniversary of the grant, and the remaining two thirds of the Options shall vest monthly over the twenty-four months following the first anniversary of the grant date.